Sebastian Giebel

List of Publications by Year
in descending order

182 papers	6,059 citations	87888 38 h-index	95266 68 g-index
188 all docs	188 docs citations	188 times ranked	5895 citing authors

#	Article	IF	Citations
1	Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood, 2003, 102, 814-819.	1.4	515
2	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematology,the, 2020, 7, e157-e167.	4.6	319
3	Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study. Journal of Clinical Oncology, 2012, 30, 2441-2448.	1.6	214
4	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. New England Journal of Medicine, 2021, 385, 228-238.	27.0	209
5	Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplantation, 2016, 51, 1431-1438.	2.4	161
6	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica, 2016, 101, 1524-1533.	3.5	154
7	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Advances, 2017, 1, 2742-2755.	5.2	151
8	Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2016, 122, 2941-2951.	4.1	140
9	Status of minimal residual disease after induction predicts outcome in both standard and highâ€risk Phâ€negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4â€2002 MRD Study. British Journal of Haematology, 2008, 142, 227-237.	2.5	134
10	Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and Gâ€CSF (CLAGâ€M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. European Journal of Haematology, 2008, 80, 115-126.	2.2	122
11	Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. Journal of Clinical Oncology, 2015, 33, 3144-3151.	1.6	119
12	Anti-thymocyte globulin as graft- versus -host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2017, 102, 224-234.	3.5	108
13	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2019, 54, 798-809.	2.4	106
14	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplantation, 2020, 55, 1114-1125.	2.4	97
15	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood, 2015, 126, 2062-2069.	1.4	93
16	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2020, 105, 1507-1516.	3.5	91
17	Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2017, 102, 139-149.	3.5	88
18	Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning. Journal of Clinical Oncology, 2010, 28, 3344-3351.	1.6	83

#	Article	IF	Citations
19	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia â€“ a matched pair analysis by the Acute Leukaemia Working Party of EBMT. British Journal of Haematology, 2019, 184, 782-787.	2.5	82
20	B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells. Experimental Hematology, 2005, 33, 480-486.	0.4	74
21	Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: A survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer, 2014, 120, 2760-2765.	4.1	73
22	Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplantation, 2016, 51, 351-357.	2.4	68
23	Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica, 2011, 96, 1344-1350.	3.5	67
24	Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2017, 102, 1810-1822.	3.5	64
25	Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. European Journal of Cancer, 2014, 50, 411-417.	2.8	60
26	Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. Journal of Hematology and Oncology, 2017, 10, 113.	17.0	60
27	Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. Journal of Hematology and Oncology, 2016, 9, 25.	17.0	57
28	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2019, 54, 519-530.	2.4	54
29	The First Immediate Face Transplant in the World. Annals of Surgery, 2016, 263, e36-e39.	4.2	52
30	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. Journal of Hematology and Oncology, 2019, 12, 108.	17.0	51
31	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica, 2020, 105, 47-58.	3.5	51
32	Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Journal of Hematology and Oncology, 2021, 14, 53.	17.0	51
33	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology, 2019, 24, 337-348.	1.5	48
34	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. Leukemia, 2020, 34, 283-292.	7.2	48
35	Does the KIR2DS5 Gene Protect from Some Human Diseases?. PLoS ONE, 2010, 5, e12381.	2.5	45
36	Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. Bone Marrow Transplantation, 2015, 50, 1495-1502.	2.4	44

#	Article	IF	Citations
37	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1406-1414.	2.0	44
38	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. Journal of Hematology and Oncology, 2020, 13, 87.	17.0	44
39	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Haematologica, 2016, 101, 256-262.	3.5	42
40	Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk groupâ€“an observational analysis by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2015, 50, 1063-1068.	2.4	41
41	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget, 2016, 7, 43027-43038.	1.8	40
42	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. European Journal of Cancer, 2018, 96, 73-81.	2.8	40
43	Reduction of DMSO concentration in cryopreservation mixture from 10% to 7.5% and 5% has no impact on engraftment after autologous peripheral blood stem cell transplantation: results of a prospective, randomized study. Bone Marrow Transplantation, 2018, 53, 274-280.	2.4	39
44	Activating killer immunoglobulinâ€like receptor incompatibilities enhance graftâ€versusâ€host disease and affect survival after allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2009, 83, 343-356.	2.2	38
45	Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. Blood, 2010, 116, 122-128.	1.4	36
46	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2021, 56, 532-535.	2.4	36
47	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transplantation, 2022, 57, 215-223.	2.4	36
48	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. Haematologica, 2016, 101, 773-780.	3.5	35
49	Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. European Journal of Haematology, 2011, 86, 488-495.	2.2	34
50	Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. Blood, 2016, 127, 360-362.	1.4	34
51	Thiotepaâ€based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matchedâ€pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 2017, 92, 997-1003.	4.1	34
52	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. Blood Advances, 2018, 2, 2127-2135.	5.2	34
53	Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). International Journal of Infectious Diseases, 2010, 14, e132-e140.	3.3	33
54	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 218-224.	2.4	32

#	Article	IF	Citations
55	G-CSF Administered in Time-sequenced Setting During Remission Induction and Consolidation Therapy of Adult Acute Lymphoblastic Leukemia has Beneficial Influence on Early Recovery and Possibly Improves Long-term Outcome: A Randomized Multicenter Study. Leukemia and Lymphoma, 2002, 43, 315-325.	1.3	31
56	Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. British Journal of Haematology, 2005, 131, 483-486.	2.5	31
57	A faster reconstitution of hematopoiesis after autologous transplantation of hematopoietic cells cryopreserved in 7.5% dimethyl sulfoxide if compared to 10% dimethyl sulfoxide containing medium. Cryobiology, 2013, 67, 327-331.	0.7	31
58	Longâ€term followâ€up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2016, 122, 1880-1887.	4.1	31
59	Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. Cancer, 2017, 123, 1965-1970.	4.1	31
60	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2019, 186, 767-776.	2.5	31
61	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia, 2020, 34, 2766-2775.	7.2	30
62	Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. Haematologica, 2021, 106, 1591-1598.	3.5	29
63	Association of circulating regulatory <scp>T</scp> cell number with the incidence and prognosis of diffuse large <scp>B</scp>â€cell lymphoma. European Journal of Haematology, 2013, 91, 122-128.	2.2	28
64	Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study. PLoS ONE, 2016, 11, e0150637.	2.5	28
65	Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematology,the, 2022, 9, e14-e25.	4.6	27
66	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematology,the, 2021, 8, e205-e215.	4.6	26
67	MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. PLoS ONE, 2016, 11, e0155893.	2.5	26
68	Sequential recovery of NK cell receptor repertoire after allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2010, 45, 1022-1030.	2.4	25
69	The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2013, 48, 238-242.	2.4	25
70	First Complex Allotransplantation of Neck Organs. Annals of Surgery, 2017, 266, e19-e24.	4.2	25
71	Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study. International Journal of Radiation Oncology Biology Physics, 2018, 102, 515-526.	0.8	25
72	Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study. Annals of Hematology, 2019, 98, 2197-2211.	1.8	25

#	Article	IF	Citations
73	Treosulfan and fludarabine lowâ€toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. British Journal of Haematology, 2008, 142, 284-292.	2.5	24
74	Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. American Journal of Hematology, 2017, 92, 359-366.	4.1	24
75	Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Annals of Hematology, 2019, 98, 2389-2398.	1.8	24
76	Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). Annals of Hematology, 2006, 85, 717-722.	1.8	23
77	Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2018, 53, 1001-1009.	2.4	23
78	Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT. Blood, 2015, 126, 863-863.	1.4	23
79	Serum Leptin and Ghrelin Levels in Premenopausal Women with Stable Body Mass Index during Treatment of Thyroid Dysfunction. Thyroid, 2008, 18, 545-550.	4.5	22
80	Plerixafor to rescue failing chemotherapy-based stem cell mobilization: itâ€™s not too late. Leukemia and Lymphoma, 2011, 52, 1711-1719.	1.3	22
81	Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. Oncotarget, 2017, 8, 112972-112979.	1.8	22
82	Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Phâ€negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 2018, 93, 778-785.	4.1	21
83	Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years. Annals of Hematology, 2009, 88, 1005-1013.	1.8	20
84	Antiâ€thymocyte globulin improves survival free from relapse and graftâ€versusâ€host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphiaâ€negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the <scp>EBMT</scp>. Cancer, 2018, 124, 2523-2533.	4.1	18
85	ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. American Journal of Hematology, 2017, 92, 789-796.	4.1	17
86	Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2020, 55, 595-602.	2.4	17
87	Blinatumomab vs historic standardâ€ofâ€care treatment for minimal residual disease in adults with Bâ€cell precursor acute lymphoblastic leukaemia. European Journal of Haematology, 2020, 104, 299-309.	2.2	17
88	Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. Cancer, 2022, 128, 2922-2931.	4.1	17
89	Thymic Activity and T Cell Repertoire Recovery after Autologous Hematopoietic Stem Cell Transplantation Preceded by Myeloablative Radiotherapy or Chemotherapy. Biology of Blood and Marrow Transplantation, 2016, 22, 834-842.	2.0	16
90	Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantationâ€”a retrospective study by the Acute Leukemia Working Party of EBMT. Bone Marrow Transplantation, 2020, 55, 1560-1569.	2.4	16

#	Article	IF	Citations
91	Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantationâ€"a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2021, 56, 1190-1199.	2.4	16
92	The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: A joint analysis of five randomised trials on behalf of the EWALL. European Journal of Cancer, 2012, 48, 360-367.	2.8	15
93	The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT). Frontiers in Immunology, 2018, 9, 2153.	4.8	15
94	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Biology of Blood and Marrow Transplantation, 2020, 26, 936-942.	2.0	15
95	Dasatinib (SprycelÂ®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic Significance. Blood, 2010, 116, 172-172.	1.4	15
96	Current Status and Perspectives of Irradiation-Based Conditioning Regimens for Patients with Acute Leukemia Undergoing Hematopoietic Stem Cell Transplantation. Clinical Hematology International, 2019, 1, 19.	1.7	15
97	Evaluation of Functional Marrow Irradiation Based on Skeletal Marrow Composition Obtained Using Dual-Energy Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2016, 96, 679-687.	0.8	14
98	Multi-institutional evaluation of MVCT guided patient registration and dosimetric precision in total marrow irradiation: A global health initiative by the international consortium of total marrow irradiation. Radiotherapy and Oncology, 2019, 141, 275-282.	0.6	14
99	Increased Efficacy of Stem Cell Chemomobilization with Intermediate-Dose Cytarabine Plus Granulocyte Colony-Stimulating Factor (G-CSF) Compared with G-CSF Alone in Patients with Multiple Myeloma: Results of a Randomized Trial. Biology of Blood and Marrow Transplantation, 2019, 25, 248-255.	2.0	14
100	Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: Multicenter Analysis by the Polish Adult Leukemia Group. Biology of Blood and Marrow Transplantation, 2020, 26, 1833-1839.	2.0	14
101	Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations. Frontiers in Immunology, 2020, 10, 3097.	4.8	14
102	Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2020, 55, 1763-1772.	2.4	14
103	Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. European Journal of Cancer, 2019, 106, 212-219.	2.8	13
104	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplantation and Cellular Therapy, 2022, 28, 86.e1-86.e8.	1.2	13
105	The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; The results of multicenter, prospective Polish adult leukemia group study. American Journal of Hematology, 2011, 86, 437-439.	4.1	12
106	Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP â€" the PLRG report. Scientific Reports, 2020, 10, 3517.	3.3	12
107	Infectious Complications in Patients With Multiple Myeloma After High-Dose Chemotherapy Followed by Autologous Stem Cell Transplant: Nationwide Study of the Infectious Complications Study Group of the Polish Adult Leukemia Group. Transplantation Proceedings, 2020, 52, 2178-2185.	0.6	12
108	20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. Clinical Cancer Research, 2022, 28, 1004-1012.	7.0	12

#	Article	IF	Citations
109	Thiotepaâ€based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemiaâ€"A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 2017, 92, 18-22.	4.1	11
110	Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT. Oncologist, 2016, 21, 377-383.	3.7	10
111	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016. Acta Haematologica Polonica, 2016, 47, 39-85.	0.3	10
112	What is the outcome in patients with acute leukaemia who survive severe acute graftâ€versusâ€host disease?. Journal of Internal Medicine, 2018, 283, 166-177.	6.0	10
113	Total body irradiation + fludarabine compared to busulfan + fludarabine as â€œreduced-toxicity conditioningâ€• for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 481-491.	2.4	10
114	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. Bone Marrow Transplantation, 2021, 56, 2194-2202.	2.4	10
115	Very high efficacy of intermediate-dose cytarabine in combination with G-CSF as a second-line mobilization of hematopoietic stem cells. International Journal of Hematology, 2012, 96, 287-289.	1.6	9
116	Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study. Leukemia and Lymphoma, 2015, 56, 2331-2338.	1.3	9
117	Chemotherapy Dose Adjustment for Obese Patients Undergoing Hematopoietic Stem Cell Transplantation: A Survey on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Oncologist, 2015, 20, 50-55.	3.7	9
118	Dermoscopic Follow-Up of the Skin towards Acute Graft-versus-Host-Disease in Patients after Allogeneic Hematopoietic Stem Cell Transplantation. BioMed Research International, 2016, 2016, 1-6.	1.9	9
119	Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group. Annals of Hematology, 2016, 95, 263-269.	1.8	9
120	Szczepienia ochronne u chorych dorosÅ‚ych po przeszczepieniu komÃ³rek krwiotwÃ³rczych â€“ zalecenia sekcji do spraw zakaÅ¼eÅ„ PALG. Acta Haematologica Polonica, 2017, 48, 1-9.	0.3	9
121	HLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donor. Human Immunology, 2018, 79, 403-412.	2.4	9
122	Evaluation of proinflammatory and immunosuppressive cytokines in blood and bone marrow of healthy hematopoietic stem cell donors. Cytokine, 2018, 102, 181-186.	3.2	9
123	Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 264-274.e4.	0.4	9
124	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy, 2021, 27, 171.e1-171.e8.	1.2	9
125	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 399-406.	2.4	9
126	Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with epithelial ovarian cancer. Human Immunology, 2014, 75, 508-513.	2.4	8

#	Article	IF	Citations
127	Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers. Medical Oncology, 2015, 32, 90.	2.5	8
128	Dermoscopy in near-full facial transplantation. Journal of the American Academy of Dermatology, 2015, 72, S19-S21.	1.2	8
129	Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. Journal of Clinical Apheresis, 2017, 32, 295-301.	1.3	8
130	Outcome of Tâ€cellâ€“replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2021, 127, 2507-2514.	4.1	8
131	Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry. Cytotherapy, 2021, 23, 483-487.	0.7	8
132	Follow-up of patients with mycosis fungoides after interferon Î±2b treatment failure. Postepy Dermatologii I Alergologii, 2015, 2, 67-72.	0.9	6
133	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplantÂmeasurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. Leukemia, 2021, 35, 2232-2242.	7.2	6
134	Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG). Cancers, 2021, 13, 4189.	3.7	6
135	Tandem autologous hematopoietic cell transplantation with sequential use of total marrow irradiation and high-dose melphalan in multiple myeloma. Bone Marrow Transplantation, 2021, 56, 1297-1304.	2.4	6
136	Secondary skin neoplasms in patients after autologous and allogeneic hematopoietic stem cell transplantation procedures. Advances in Clinical and Experimental Medicine, 2020, 29, 1221-1230.	1.4	6
137	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ…ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017. Acta Haematologica Polonica, 2017, 48, 55-103.	0.3	5
138	Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. Wspolczesna Onkologia, 2018, 22, 113-117.	1.4	5
139	Szczepienia ochronne u dorosÅ‚ych chorych na nowotwory hematologiczne oraz u chorych z aspleniÄ… â€“ zalecenia PTHiT i sekcji do spraw zakaÅ¼eÅ„ PALG. Acta Haematologica Polonica, 2018, 49, 93-101.	0.3	5
140	Low percentages of circulating CD8+/CD45RA+ human T lymphocytes expressing Î²7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Experimental Hematology, 2006, 34, 1429-1434.	0.4	4
141	Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (alloâ€<scp>HSCT</scp>) by analyzing survival end points in defined groups of acute myeloid leukemia patients: A retrospective, multicenter <scp>P</scp>olish <scp>A</scp>dult <scp>L</scp>eukemia <scp>G</scp>roup study. American Journal of Hematology, 2015, 90, 904-909.	4.1	4
142	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ…ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019. Acta Haematologica Polonica, 2018, 49, 157-206.	0.3	4
143	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplantation, 2022, 57, 572-578.	2.4	4
144	Immunological properties of bone marrow microenvironment 1Âyear after allogeneic hematopoietic stem cell transplantation. Experimental Hematology, 2016, 44, 1172-1180.e1.	0.4	3

#	Article	IF	Citations
145	Hodgkin lymphoma transformation of chronic lymphocytic leukemiaâ€"A real life data from the Polish Lymphoma Research Group. Hematological Oncology, 2019, 37, 383-391.	1.7	3
146	Dermoscopic followâ€up of therapeutic response in mantle cell lymphoma with secondary involvement of the scalp. Journal of Cosmetic Dermatology, 2019, 18, 1438-1440.	1.6	3
147	Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 105-113.	0.4	3
148	IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. Scientific Reports, 2021, 11, 10017.	3.3	3
149	Could cytogenetics and minimal residual disease replace conventional risk criteria in adults with Phâ€negative acute lymphoblastic leukaemia?. British Journal of Haematology, 2009, 144, 970-972.	2.5	2
150	Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of The Polish Acute Leukemia Group. Leukemia and Lymphoma, 2009, 50, 478-480.	1.3	2
151	Impact of granulocyte colony stimulating factor administered during induction and consolidation of adults with acute lymphoblastic leukemia on survival: long-term follow-up of the Polish adult leukemia group 4-96 study. Leukemia and Lymphoma, 2009, 50, 1050-1053.	1.3	2
152	Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib. Postepy Dermatologii I Alergologii, 2018, 35, 39-46.	0.9	2
153	Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT. Frontiers in Immunology, 2020, 11, 1537.	4.8	2
154	Dermoscopy of Cutaneous Graft-Versus-Host-Disease in Patients After Allogeneic Hematopoietic Stem Cell Transplantation. Dermatology and Therapy, 2020, 10, 1043-1061.	3.0	2
155	Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 1047-1055.	2.4	2
156	Clinical manifestations of diffuse large Bâ€cell lymphoma in the skin and subcutaneous tissue a case series study. Postepy Dermatologii I Alergologii, 2020, 37, 812-816.	0.9	2
157	Rytuksymab â€“ pierwsze biopodobne przeciwciaÅ‚a monoklonalne w hematoonkologii. Acta Haematologica Polonica, 2017, 48, 269-273.	0.3	1
158	Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). Leukemia and Lymphoma, 2020, 61, 588-603.	1.3	1
159	High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma. Annals of Hematology, 2021, 100, 1755-1767.	1.8	1
160	Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Case Report. Transplantation Proceedings, 2020, 52, 2551-2553.	0.6	1
161	Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG). Blood, 2016, 128, 213-213.	1.4	1
162	Injection of G-CSF During Leukaphereses Reduces the Number of Aphereses Needed for Mobilization in Unrelated Hematopoietic Stem Cell Donors. Annals of Transplantation, 2014, 19, 444-446.	0.9	1

#	Article	IF	Citations
163	Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG). Acta Haematologica Polonica, 2018, 49, 234-239.	0.3	1
164	PostÄ™py w przeszczepianiu krwiotwÃ³rczych komÃ³rek macierzystych. Hematologia, 2015, 6, 85-89.	0.0	1
165	Napromienianie szpiku caÅ‚ego ciaÅ‚a â€" prezentacja metody. Nowotwory, 2014, 64, 314-320.	0.3	1
166	Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT. Blood, 2021, 138, 2876-2876.	1.4	1
167	Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). Blood, 2021, 138, 1787-1787.	1.4	1
168	Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantationâ€ineligible relapsed and refractory diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2022, , .	2.5	1
169	Association of KIR2DS4 gene with susceptibility to leukemia: Chineseâ€"Polish discrepancy. Leukemia Research, 2011, 35, 1540.	0.8	0
170	Prognostic significance of the number and type of extra nodal localizations of DLBCL in the rituximab era. Acta Haematologica Polonica, 2015, 46, 49-55.	0.3	0
171	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ…ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2015. Acta Haematologica Polonica, 2015, 46, 159-211.	0.3	0
172	Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 4316-4316.	1.4	0
173	Stanowisko polskich ekspertÃ³w dotyczÄ…ce zastosowania leku brentuksymab vedotin w leczeniu chorych na pierwotne chÅ‚oniaki skÃ³ry CD30+. Hematologia, 2018, 9, 83-89.	0.0	0
174	Stosowanie lekÃ³w biopodobnych w hematoonkologii â€" stanowisko Polskiego Towarzystwa HematologÃ³w i TransfuzjologÃ³w. Acta Haematologica Polonica, 2019, 50, 51-56.	0.3	0
175	The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 43-43.	1.4	0
176	The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study. Blood, 2021, 138, 3453-3453.	1.4	0
177	NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry. Blood, 2020, 136, 20-21.	1.4	0
178	Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2020, 136, 6-7.	1.4	0
179	A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients â‰¥ 60 Years Old (PALG-AML1/2016). Blood, 2020, 136, 3-4.	1.4	0
180	Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients. Blood, 2020, 136, 40-42.	1.4	0

#	Article	IF	Citations
181	The impact of blood donation on bone marrow harvest efficiency. Bone Marrow Transplantation, 2022, 57, 507-509.	2.4	0
182	Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis. Bone Marrow Transplantation, 2022, , .	2.4	0